Table 1A.
Risks and benefits of obesity pharmacotherapy, diabetes medications.
| Composite CV outcomes | CV death | Non-fatal MI | Non-fatal Stroke | SBP | DBP | HR | HDL | LDL | TG | HF | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes Medications | |||||||||||
| Liraglutide 1.8 mg |  |
|
 |
|
|
 |
|
— | — | — | |
| Liraglutide 3.0 mg | |
|
|
|
|
|
|
|
|
|
NR |
| Semaglutide | |
— | |
|
|
— | |
|
|
|
 |
| Exenatide | — | |
— | |
|
|
|
NR | |
|
|
| Dulaglutide | |
|
|
|
|
— | |
|
NR | NR | |
| Lixisenatide | |
|
|
|
|
NR | |
NR | NR | NR | |
| Metformin | |
|
|
|
NR | NR | NR | NR | |
|
NR |
| SGLT2 Inhibitors | — | |
|
|
|
|
— | — | — | — | — |
Key: Black arrows indicate statistically significant change; gray arrows indicate a non-statistically significant change; NR means not reported; — indicates reported; no change. Abbreviations: CV, cardiovascular; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; HDL, high density lipoprotein; LDL, low density lipoprotein; HF, heart failure; TG, triglycerides.